Enrollment is underway in a 120-subject Phase 2/3 clinical trial evaluating Zosano Pharma’s (ZSAN +3.5%) C213 (zolmitriptan) for the acute treatment of cluster headache.
C213 is a patch worn on the skin based on the
company’s ADAM technology, drug-coated titanium micro-projections that
deliver the drug through the skin. It is the same approach used with
migraine patch Qtrypta.
The co-primary endpoints are the proportion of
patients achieving pain relief within 15 minutes and the proportion of
patients achieving sustained pain relief (15 minutes to 60 minutes).
The estimated completion date is April 2021.
https://seekingalpha.com/news/3509144-zosano-launches-phase-2-3-study-zolmitriptan-cluster-headache
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.